Engraftment, hospitalization time, and transplantation-related toxicity
. | Arm A HDM140/TBI (n = 140) . | Arm B HDM200 (n = 142) . | P . |
---|---|---|---|
G/GM-CSF (%) | 111 (79) | 107 (75) | .52 |
Duration of G/GM-CSF, d (median) | 0-25 (8) | 0-23 (7) | .37 |
Duration of neutropenia, d (median) | 4-34 (10) | 4-34 (8) | < .001 |
Duration of thrombocytopenia, d (median) | 0-110 (7) | 0-30 (7) | < .001 |
No. of platelet transfusions (median) | 0-30 (2) | 0-18 (1) | < .001 |
No. of red blood cell transfusions (median) | 2 (0-22) | 2 (0-9) | < .001 |
Duration of hospitalization, d (median) | 12-77 (23) | 11-47 (19) | < .001 |
Duration of intravenous antibiotics, d (median) | 0-60 (11) | 0-30 (8) | < .001 |
Cardiac toxicity grade 3-4 (%) | 5 (3.6) | 1 (0.7) | .21 |
Mucositis grade 3-4 (%) | 71 (51) | 42 (30) | < .001 |
Pulmonary toxicity grade 3-4 (%) | 9 (6.4) | 2 (1.4) | .06 |
Renal toxicity grade 3-4 (%) | 5 (3.6) | 3 (2.1) | .7 |
Liver toxicity grade 3-4 (%) | 2 (1.4) | 1 (0.7) | .99 |
Toxic death (%) | 5 (3.6) | 0 | .07 |
. | Arm A HDM140/TBI (n = 140) . | Arm B HDM200 (n = 142) . | P . |
---|---|---|---|
G/GM-CSF (%) | 111 (79) | 107 (75) | .52 |
Duration of G/GM-CSF, d (median) | 0-25 (8) | 0-23 (7) | .37 |
Duration of neutropenia, d (median) | 4-34 (10) | 4-34 (8) | < .001 |
Duration of thrombocytopenia, d (median) | 0-110 (7) | 0-30 (7) | < .001 |
No. of platelet transfusions (median) | 0-30 (2) | 0-18 (1) | < .001 |
No. of red blood cell transfusions (median) | 2 (0-22) | 2 (0-9) | < .001 |
Duration of hospitalization, d (median) | 12-77 (23) | 11-47 (19) | < .001 |
Duration of intravenous antibiotics, d (median) | 0-60 (11) | 0-30 (8) | < .001 |
Cardiac toxicity grade 3-4 (%) | 5 (3.6) | 1 (0.7) | .21 |
Mucositis grade 3-4 (%) | 71 (51) | 42 (30) | < .001 |
Pulmonary toxicity grade 3-4 (%) | 9 (6.4) | 2 (1.4) | .06 |
Renal toxicity grade 3-4 (%) | 5 (3.6) | 3 (2.1) | .7 |
Liver toxicity grade 3-4 (%) | 2 (1.4) | 1 (0.7) | .99 |
Toxic death (%) | 5 (3.6) | 0 | .07 |